Horizon Pharma PLC (HZNP) Upgraded at ValuEngine

ValuEngine upgraded shares of Horizon Pharma PLC (NASDAQ:HZNP) from a hold rating to a buy rating in a research note issued to investors on Monday.

Other research analysts have also issued research reports about the company. BidaskClub raised Horizon Pharma PLC from a hold rating to a buy rating in a research report on Saturday, June 24th. UBS AG set a $16.00 price target on Horizon Pharma PLC and gave the company a buy rating in a research report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 price target on Horizon Pharma PLC and gave the company a buy rating in a research report on Monday, August 7th. Cantor Fitzgerald set a $13.00 price target on Horizon Pharma PLC and gave the company a buy rating in a research report on Monday, July 31st. Finally, BMO Capital Markets reaffirmed a buy rating and set a $17.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $18.00.

Horizon Pharma PLC (NASDAQ HZNP) traded down 0.22% during midday trading on Monday, reaching $13.80. The company had a trading volume of 554,428 shares. The company has a 50-day moving average price of $13.13 and a 200-day moving average price of $12.68. The stock’s market capitalization is $2.25 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. Horizon Pharma PLC’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.56 EPS. On average, equities analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/10/19/horizon-pharma-plc-hznp-upgraded-at-valuengine.html.

Several institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. grew its stake in shares of Horizon Pharma PLC by 2.6% in the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 420 shares during the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma PLC by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares during the last quarter. Amalgamated Bank grew its stake in shares of Horizon Pharma PLC by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 943 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Horizon Pharma PLC by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,378 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Horizon Pharma PLC by 1.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock worth $1,495,000 after buying an additional 1,379 shares during the last quarter. Institutional investors own 82.32% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

What are top analysts saying about Horizon Pharma PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Horizon Pharma PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit